Jonathan Zalevsky Sells 51,115 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock

Nektar Therapeutics (NASDAQ:NKTR) insider Jonathan Zalevsky sold 51,115 shares of the stock in a transaction that occurred on Thursday, December 19th. The shares were sold at an average price of $0.94, for a total value of $48,048.10. Following the transaction, the insider now owns 326,904 shares in the company, valued at $307,289.76. This trade represents a 13.52 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jonathan Zalevsky also recently made the following trade(s):

• On Tuesday, November 19th, Jonathan Zalevsky sold 7,785 shares of Nektar Therapeutics stock. The stock was sold at an average price of $1.01, for a total transaction of $7,862.85.

Nektar Therapeutics Trading Down 1.3 %

Shares of NASDAQ NKTR opened at $0.93 on Friday. The stock has a market cap of $171.23 million, a PE ratio of -1.11 and a beta of 0.57. Nektar Therapeutics has a 12-month low of $0.46 and a 12-month high of $1.93. The company has a 50-day moving average of $1.18 and a 200 day moving average of $1.23.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC lifted its position in Nektar Therapeutics by 63.0% during the second quarter. SG Americas Securities LLC now owns 73,352 shares of the biopharmaceutical company’s stock worth $91,000 after buying an additional 28,338 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Nektar Therapeutics by 2,822.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 551,535 shares of the biopharmaceutical company’s stock worth $684,000 after acquiring an additional 532,663 shares during the period. Rhumbline Advisers boosted its position in shares of Nektar Therapeutics by 3,377.0% during the 2nd quarter. Rhumbline Advisers now owns 185,116 shares of the biopharmaceutical company’s stock valued at $230,000 after acquiring an additional 179,792 shares during the last quarter. Victory Capital Management Inc. acquired a new position in shares of Nektar Therapeutics during the 2nd quarter valued at about $29,000. Finally, Candriam S.C.A. purchased a new stake in shares of Nektar Therapeutics in the second quarter valued at about $99,000. 75.88% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on NKTR shares. BTIG Research reiterated a “buy” rating and issued a $4.00 target price on shares of Nektar Therapeutics in a research report on Monday, September 30th. Piper Sandler began coverage on Nektar Therapeutics in a report on Monday, November 4th. They issued an “overweight” rating and a $7.00 price objective on the stock. Finally, HC Wainwright initiated coverage on Nektar Therapeutics in a research report on Tuesday, December 10th. They issued a “buy” rating and a $6.50 target price on the stock. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $4.10.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.